Diastolic blood pressure reduction contributes more to the regression of left ventricular hypertrophy: A meta-analysis of randomized controlled trials

Journal of Human Hypertension

Volumn 27, Issue 11, 2013, Pages 698-706

  Zhang, K ^a,b   Chen, J ^b   Liu, Y ^b   Wang, T ^b   Wang, L ^b   Wang, J ^a,b   Huang, H ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology   (China)

Author keywords

diastolic blood pressure; left ventricular hypertrophy; left ventricular hypertrophy index; regression; systolic blood pressure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; COMPARATIVE STUDY; DATA EXTRACTION; DIASTOLIC BLOOD PRESSURE; DRUG CLASSIFICATION; ECHOCARDIOGRAPHY; EMBASE; ESSENTIAL HYPERTENSION; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SAMPLE SIZE; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIASTOLE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SYSTOLE; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84885584146     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.20     Document Type: Article

References (40)

1. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108: 7-13.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
3. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-586.
4. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334-341.
5. Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K et al. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention for Endpoint Reduction study. J Hypertens 2002; 20: 1445-1450.
6. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-536.
7. Verdecchia P, Angeli F, Gattobigio R, Guerrieri M, Benemio G, Porcellati C. Does the reduction in systolic blood pressure alone explain the regression of left ventricular hypertrophy? J Hum Hypertens 2004; 18(Suppl 2): S23-S528.
8. Okin PM, Hille DA, Kjeldsen SE, Dahlof B, Devereux RB. Impact of lower achieved blood pressure on outcomes in hypertensive patients. J Hypertens 2012; 30: 802-810.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
10. Jiang N, Wang B, Chen A, Dong F, Yu B. Operative versus nonoperative treatment for acute Achilles tendon rupture: a meta-analysis based on current evidence. Int Orthop 2012; 36: 765-773.
11. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet 2008; 371: 2219-2221.
12. Sever P. Is systolic blood pressure all that matters? Yes. BMJ 2009; 339: b2665.
13. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010; 31: 2897-2908.
14. O'Brien E. Is systolic blood pressure all that matters? No. BMJ 2009; 339: b2669.
15. Batkai S, Thum T. MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr Hypertens Rep 2012; 14: 79-87.
16. Burns J, Ball SG, Worthy G, Struthers AD, Mary DA, Greenwood JP. Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance. J Hypertens 2012; 30: 2039-2046.
17. Franklin SS, Wt Gustin, Wong ND, Larson MG, Weber MA, Kannel WB et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308-315.
18. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham Heart Study. Circulation 1999; 100: 354-360.
19. Orias M, Tabares AH, Peixoto AJ. Hypothesis: it is time to reconsider phenotypes in hypertension. J Clin Hypertens (Greenwich) 2010; 12: 350-356.
20. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.
21. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
22. Cushman WC, Evans GW, Byington RP, Goff Jr. DC, Grimm Jr RH, Cutler JA et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.
23. Okin PM. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2003; 108: 684-690.
24. Machnig T, Henneke KH, Engels G, Pongratz G, Schmalzl M, Gellert J et al. Nitrendipine vs. captopril in essential hypertension: effects on circadian blood pressure and left ventricular hypertrophy. Cardiology 1994; 85: 101-110.
25. Fogari R, Zoppi A, Mugellini A, Tettamanti F, Lusardi P, Corradi L. Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension. Eur Heart J 1995; 16: 1120-1125.
26. Tedesco MA, Ratti G, Aquino D, Limongelli G, di Salvo G, Mennella S et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998; 12: 505-510.
27. Hoglund C, Cifkova R, Mimran A, Tenczer J, Watt A, Wilkins MR et al. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients. Cardiology 1998; 89: 263-270.
28. Agabiti-Rosei E, Zulli R, Muiesan ML, Salvetti M, Rizzoni D, Corbellini C et al. Reduction of cardiovascular structural changes by nifedipine GITS in essential hypertensive patients. Blood Press 1998; 7: 160-169.
29. Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037-2042.
30. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18: 1465-1475.
31. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001; 104: 1248-1254.
32. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-2300.
33. Gaudio C, Ferri FM, Giovannini M, Pannarale G, Puddu PE, Vittore A et al. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol 2003; 42: 622-628.
34. Galzerano D, Tammaro P, Cerciello A, Breglio R, Mallardo M, Lama D et al. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J Hum Hypertens 2004; 18: 53-59.
35. de Luca N, Mallion JM, O'Rourke MF, O'Brien E, Rahn KH, Trimarco B et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/ indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004; 17: 660-667.
36. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004; 43: 2116-2123.
37. Agabiti-Rosei E, Trimarco B, Muiesan ML, Reid J, Salvetti A, Tang R et al. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2005; 23: 1091-1098.
38. Rosendorff C, Dubiel R, Xu J, Chavanu KJ. Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy. Am J Cardiol 2009; 104: 359-365.
39. Yamamoto K, Ozaki H, Takayasu K, Akehi N, Fukui S, Sakai A et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertens Res 2011; 34: 325-330.
40. Fogari R, Mugellini A, Destro M, Corradi L, Lazzari P, Zoppi A et al. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. Diabet Med 2012; 29: 24-31.